PRTC(Delisted)
Stock Fundamental
Valuation4.3/10
NeutralKey Valuation Metric
PE Method: PRTC's market cap is approximately 424.03M with TTM earnings of -10.97B, corresponding to a PE ratio of -3.9. Compared to the Pharmaceuticals industry average, this valuation may be undervalued.
PS Method: PRTC's market cap is approximately 424.03M with a PS ratio of 91.0. Compared to the Pharmaceuticals industry average, this valuation may be overvalued.
PEG Method: With a PE of -3.9 and forward PE of -3.8, the PEG ratio comes to 1.00, indicating a reasonable valuation.
Historical Price to Earnings Ratio
Historical data shows that PRTC's P/E reached a peak of about 9.41 on 2025-08-18, and a trough of about -17.65 on 2023-07-11. The current P/E is -3.86, which places it at approximately the 51% percentile of its historical range, indicating a relatively reasonable valuation.
Share Price vs Future Cash Flow Value
Future Growth4.0/10
NeutralEarnings and Revenue Growth Forecasts
No forecast data
Future Return on Equity
Analysts predict PRTC's future return on equity (Future ROE) will be about -26.4% over the next three years, higher than the Pharmaceuticals industry average of -102.3%, indicating its leading position in capital profitability. A higher Future ROE generally reflects stronger expected profitability on shareholder equity, subject to business risk and accounting differences.
Past Performance3.1/10
NeutralRevenue & Expenses Breakdown
Earnings & Revenue
No earnings data
Free Cash Flow vs Earnings Analysis
No FCF bridge data
Financial Health6.7/10
NeutralDebt to Equity History and Analysis
In 2025-12, total liabilities (Debt) are about 229.03M; total equity (Equity) is about 305.68M. These figures come from the financial health diagnose series (debt / equity). They describe capital structure, not operating earnings.
Balance Sheet
Assets
Liabilities + Equity
The company's shareholders' equity is $305.68M, representing about 57.2% of total assets, while total debt is $182.73M, representing about 34.2% of total assets. This low-leverage structure means expansion relies primarily on profits and equity capital, resulting in lower financial risk.
Dividends4.0/10
NeutralStability and Growth of Payments
No dividend stability data
Dividend Yield vs Market
PRTC's current dividend yield is 0.00%, while the Pharmaceuticals industry average is around 3.56%. The top 25% of companies in the entire US market have a dividend yield of 4.56%, while the bottom 25% have a yield of 2.48%. In comparison, PRTC is clearly at the bottom of the industry.
Earnings Payout to Shareholders
Earnings coverage: PRTC is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash flow coverage: PRTC is not paying a notable dividend for the US market.
- Based on a composite score of 5.39/10, we rate PRTC as a Netural. Our analysis breaks down into 2.50/10 for Fundamentals, 3.75/10 for Technicals, and 6.82/10 for Sentiment, indicating the stock is likely to consolidate sideways.
- Based on a composite score of 5.39/10, we rate PRTC as a Netural. Our analysis breaks down into 2.50/10 for Fundamentals, 3.75/10 for Technicals, and 6.82/10 for Sentiment, indicating the stock is likely to consolidate sideways.
